Ethical Challenges in Genetic Editing of Haematologic Disorders: Patient Consent and Social Implications

Read full text Summarise with VIRAT
Authors: Ankit Kishor Badge, Brij Raj Singh, Maithili Bankar, Nandkishor Jageshwar Bankar, Dayanand P. Gogle
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Genetic editing is a transformative technology in the treatment and management of haematologic disorders. Genome-editing technique has the potential to correct disease-causing mutations at the molecular level. However, these advances are transformative, but this technique is also surrounded by complex ethical challenges. Informed consent remains one of the most pressing ethical concerns. Furthermore, social inequities are important in determining access to these therapies. The treatment costs are also very expensive, which will be only accessible to patients in wealthy regions. The resource-constrained countries are facing challenges that include inadequate infrastructure, lack of regulatory frameworks and limited financial resources. Gene editing in haematologic disorders is advanced but raises key ethical and practical concerns. Germline editing is opposed due to safety risks and potential social inequality. In paediatric cases, it can create a problem in future autonomy. Further challenges include a lack of long-term data, global standards and high costs. Ethical guidelines, public engagement, cost subsidies and long-term research are important. A balanced, patient-centred approach is essential for responsible use of this gene-editing technology.

Fields of Study & Subjects

Ethics and bioethics in healthcare CRISPR and Genetic Engineering Biomedical Ethics and Regulation

Publication details

Journal / source
Advances in Human Biology
Volume
16
Issue
4
Pages
672–674
Publication date
20 March 2026
Language
EN